MedTrace Logo

Diagnosing Adverse Drug Reactions Registry

NCT01970709 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250000

Last updated 2015-03-19

No results posted yet for this study

Summary

This multicenter Registry is to assess whether the use of pharmacogenomic data results in a meaningful change in a subject's drug or dose regimen. In addition, the Registry will evaluate the relationship between adverse drug reactions (ADR) and genotype and assess resource utilization (emergency department visits and hospitalizations) associated with ADR.

Conditions

  • Genetics of Drug Metabolism

Sponsors & Collaborators

  • Syntactx

    collaborator NETWORK

  • Renaissance RX

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01970709 on ClinicalTrials.gov